APBA2 and colorectal carcinoma: In the study by Van Rijnsoever and colleagues, CIMP+ (based on a panel of three methylation markers including Cyclin Dependent Kinase Inhibitor 2A, Methylated-IN-Tumour locus 2, and Multi Drug Reactivity 1 genes; CDKN2A, MINT-2 and MDR1, respectively) was associated with worse prognosis in CRC patients treated with surgery alone [48].